Table 4 Application of the proposed method for the determination of the drugs in dosage forms.
Parameter | Proposed method | Comparison method65 | ||
|---|---|---|---|---|
Conc.taken (μM) | Conc.found (μM) | % recoverya | % recoverya | |
RFP | ||||
REP capsules (300 mg/capsule) | 5.0 | 5.09 | 101.91 | 101.19 |
10.0 | 9.89 | 98.87 | 97.9 | |
15.0 | 14.90 | 99.36 | 97.8 | |
Mean | 100.05 | 98.96 | ||
± SD | 1.63 | 1.93 | ||
% RSD | 1.628 | 1.949 | ||
Student t-test | 0.74 (2.77)b | |||
Variance ratio F-value | 1.39 (19.0)b | |||
Parameter | Proposed method | Comparison method14 | ||
|---|---|---|---|---|
Conc.taken (μM) | Conc.found (μM) | % recoverya | % recoverya | |
TNZ | ||||
Protozole® coated tablets (TNZ, 500 mg/tablet) | 50.0 | 49.57 | 99.14 | 97.7 |
100.0 | 101.67 | 101.67 | 97.39 | |
150.0 | 147.71 | 98.47 | 95.19 | |
Mean | 99.76 | 96.76 | ||
± SD | 1.69 | 1.37 | ||
% RSD | 1.691 | 1.412 | ||
Student t-test | 2.39 (2.77)b | |||
Variance ratio F-value | 1.52 (19.0)b | |||
Parameter | Proposed method | Comparison method13 | ||
|---|---|---|---|---|
Conc.taken (μM) | Conc.found (μM) | % recoverya | % recoverya | |
ONZ | ||||
Astranida® coated tablets (ONZ, 500 mg/tablet) | 25.0 | 24.66 | 98.64 | 98.9 |
50.0 | 48.64 | 97.80 | 101.14 | |
75.0 | 76.02 | 101.36 | 102.08 | |
Mean | 99.27 | 100.71 | ||
± SD | 1.86 | 1.63 | ||
% RSD | 1.875 | 1.623 | ||
Student t-test | 1.01 (2.78)b | |||
Variance ratio F-value | 1.29 (19.0)b | |||
Parameter | Proposed method | Comparison method12 | ||
|---|---|---|---|---|
Conc.taken (μM) | Conc.found (μM) | % recoverya | % recoverya | |
MNZ | ||||
Flagyl® coated tablets (MNZ, 500 mg/tablet) | 10.0 | 9.95 | 99.48 | 98.2 |
25.0 | 24.83 | 99.31 | 98.9 | |
40.0 | 39.81 | 99.53 | 99.1 | |
Mean | 99.44 | 98.73 | ||
± SD | 0.12 | 0.47 | ||
% RSD | 0.116 | 0.479 | ||
Student t-test | 2.52 (2.78)b | |||
Variance ratio F-value | 16.79 (19.0)b | |||
